195 related articles for article (PubMed ID: 31899815)
21. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
22. Ameloblastic Fibrosarcoma of the Jaw: Case Report, Genetic Profiling, and Literature Review.
Barakeh D; Alsolami A; Abedalthagafi M
Case Rep Oncol; 2023; 16(1):1293-1299. PubMed ID: 37942402
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
24. Ameloblastic fibrosarcoma of the mandible: report of 2 chemosensitive pediatric cases.
Demoor-Goldschmidt C; Minard-Colin V; Cassagneau E; Supiot S; Oberlin O; D'hautuille C; Corradini N
J Pediatr Hematol Oncol; 2012 Mar; 34(2):e72-6. PubMed ID: 22009005
[TBL] [Abstract][Full Text] [Related]
25. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
26. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
27. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR.
Kao EY; Wakeman KM; Wu Y; Gross JM; Chen EY; Ricciotti RW; Liu YJ; Mantilla JG
Hum Pathol; 2022 Nov; 129():90-97. PubMed ID: 36067829
[TBL] [Abstract][Full Text] [Related]
29. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
[TBL] [Abstract][Full Text] [Related]
31. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
32. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
[TBL] [Abstract][Full Text] [Related]
34. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
35. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
36. Differential Outcomes in Codon 12/13 and Codon 61
Cleary JM; Wang V; Heist RS; Kopetz ES; Mitchell EP; Zwiebel JA; Kapner KS; Chen HX; Li S; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Meric-Bernstam F; Dillmon MS; Williams PM; Hamilton SR; Conley BA; Aguirre AJ; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT
Clin Cancer Res; 2021 Jun; 27(11):2996-3004. PubMed ID: 33637626
[TBL] [Abstract][Full Text] [Related]
37. Ameloblastic fibroma and ameloblastic fibrosarcoma: A systematic review.
Chrcanovic BR; Brennan PA; Rahimi S; Gomez RS
J Oral Pathol Med; 2018 Apr; 47(4):315-325. PubMed ID: 28776760
[TBL] [Abstract][Full Text] [Related]
38. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
[TBL] [Abstract][Full Text] [Related]
39. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
[TBL] [Abstract][Full Text] [Related]
40. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
